Skip to main content

Ancef Disease Interactions

There are 6 disease interactions with Ancef (cefazolin).

Major

Antibiotics (applies to Ancef) colitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious)

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

References

  1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories PROD (2002):
  2. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome PROD (2002):
  3. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome PROD (2002):
  4. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn PROD (2002):
  5. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals PROD (2002):
  6. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals PROD (2002):
  7. "Product Information. Amoxil (amoxicillin)." SmithKline Beecham PROD (2001):
  8. "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals PROD (2001):
  9. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis PROD (2001):
  10. "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn PROD (2001):
  11. "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc (2003):
  12. "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals (2004):
  13. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical (2007):
  14. "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc (2009):
  15. "Product Information. Vibativ (telavancin)." Theravance Inc (2009):
  16. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals (2010):
  17. "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc (2022):
  18. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc. (2014):
  19. "Product Information. Orbactiv (oritavancin)." The Medicines Company (2014):
  20. "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions (2017):
  21. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc. (2017):
  22. "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC (2022):
  23. "Product Information. Zemdri (plazomicin)." Achaogen (2018):
  24. "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
  25. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
  26. "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc. (2018):
  27. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
  28. "Product Information. Biaxin (clarithromycin)." AbbVie US LLC SUPPL-61 (2019):
  29. "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group LAB-0372-7.0 (2021):
  30. "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals SUPPL-74 (2018):
  31. "Product Information. Priftin (rifapentine)." sanofi-aventis SUPPL-18 (2020):
  32. "Product Information. Xerava (eravacycline)." Tetraphase Pharmaceuticals, Inc (2021):
  33. "Product Information. Xacduro (durlobactam-sulbactam)." La Jolla Pharmaceutical ORIG-1 (2023):
View all 33 references
Moderate

Beta-lactams (parenteral) (applies to Ancef) renal dysfunction

Moderate Potential Hazard, High plausibility.

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function. Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents. Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.

References

  1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories PROD (2002):
  2. "Product Information. Ancef (cefazolin)." SmithKline Beecham PROD (2002):
  3. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn PROD (2002):
  4. "Product Information. Monocid (cefonicid)." SmithKline Beecham PROD (2002):
  5. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel PROD (2002):
  6. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals PROD (2002):
  7. "Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc PROD (2002):
  8. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome PROD (2002):
  9. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham PROD (2002):
  10. "Product Information. Cefizox (ceftizoxime)." Fujisawa PROD (2002):
  11. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome PROD (2002):
  12. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome PROD (2002):
  13. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company PROD (2002):
  14. "Product Information. Cefadyl (cephapirin)." Apothecon Inc PROD (2002):
  15. "Product Information. Staphcillin (methicillin)." Apothecon Inc PROD (2002):
  16. "Product Information. Pfizerpen (penicillin)." Roerig Division PROD (2001):
  17. "Product Information. Pipracil (piperacillin)." Lederle Laboratories PROD (2001):
  18. "Product Information. Ticar (ticarcillin)." SmithKline Beecham PROD (2001):
  19. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company PROD (2001):
  20. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb PROD (2001):
  21. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
View all 21 references
Moderate

Cefazolin (applies to Ancef) sodium

Moderate Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Hypernatremia, Fluid Retention, Hypertension

Parenteral cefazolin sodium contains approximately 46 mg (2 mEq) of sodium per each gram of cefazolin activity. The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.

References

  1. "Product Information. Ancef (cefazolin)." SmithKline Beecham PROD (2002):
  2. "Product Information. Kefzol (cefazolin)." Lilly, Eli and Company PROD (2002):
Moderate

Cephalosporins (applies to Ancef) dialysis

Moderate Potential Hazard, High plausibility. Applicable conditions: hemodialysis

Most cephalosporin antibiotics are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis. Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.

References

  1. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company PROD (2002):
  2. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb PROD (2002):
  3. "Product Information. Ancef (cefazolin)." SmithKline Beecham PROD (2002):
  4. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc PROD (2002):
  5. "Product Information. Monocid (cefonicid)." SmithKline Beecham PROD (2002):
  6. "Product Information. Cefobid (cefoperazone)." Roerig Division PROD (2002):
  7. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel PROD (2002):
  8. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals PROD (2002):
  9. "Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc PROD (2002):
  10. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn PROD (2002):
  11. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb PROD (2002):
  12. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham PROD (2002):
  13. "Product Information. Cefizox (ceftizoxime)." Fujisawa PROD (2002):
  14. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories PROD (2002):
  15. "Product Information. Keflex (cephalexin)." Dista Products Company PROD (2002):
  16. "Product Information. Velosef (cephradine)." Apothecon Inc PROD (2002):
  17. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company PROD (2002):
  18. "Product Information. Cefadyl (cephapirin)." Apothecon Inc PROD (2002):
  19. "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company PROD (2002):
  20. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company PROD (2001):
  21. "Product Information. Cedax (ceftibuten)." Schering-Plough PROD (2001):
  22. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb PROD (2001):
  23. "Product Information. Omnicef (cefdinir)." Parke-Davis PROD (2001):
  24. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
View all 24 references
Moderate

Cephalosporins (applies to Ancef) liver disease

Moderate Potential Hazard, Moderate plausibility.

Cases of hepatitis have been reported with the use of certain cephalosporins. Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed. Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.

References

  1. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn PROD
  2. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company PROD (2002):
  3. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb PROD (2002):
  4. "Product Information. Ancef (cefazolin)." SmithKline Beecham PROD (2002):
  5. "Product Information. Kefzol (cefazolin)." Lilly, Eli and Company PROD (2002):
  6. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc PROD (2002):
  7. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel PROD (2002):
  8. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals PROD (2002):
  9. "Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc PROD (2002):
  10. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb PROD (2002):
  11. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome PROD (2002):
  12. "Product Information. Cefizox (ceftizoxime)." Fujisawa PROD (2002):
  13. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome PROD (2002):
  14. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome PROD (2002):
  15. "Product Information. Keflex (cephalexin)." Dista Products Company PROD (2002):
  16. "Product Information. Cedax (ceftibuten)." Schering-Plough PROD (2001):
  17. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb PROD (2001):
  18. "Product Information. Omnicef (cefdinir)." Parke-Davis PROD (2001):
  19. "Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals PROD (2001):
  20. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
View all 20 references
Moderate

Cephalosporins (applies to Ancef) seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

Cephalosporins have been implicated in triggering seizures. Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment. Adjust dosing based on creatinine clearance. Anticonvulsant therapy should be continued in patients with known seizure disorders. If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.

References

  1. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn PROD
  2. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company PROD (2002):
  3. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb PROD (2002):
  4. "Product Information. Ancef (cefazolin)." SmithKline Beecham PROD (2002):
  5. "Product Information. Kefzol (cefazolin)." Lilly, Eli and Company PROD (2002):
  6. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc PROD (2002):
  7. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel PROD (2002):
  8. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals PROD (2002):
  9. "Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc PROD (2002):
  10. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb PROD (2002):
  11. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome PROD (2002):
  12. "Product Information. Cefizox (ceftizoxime)." Fujisawa PROD (2002):
  13. "Product Information. Keflex (cephalexin)." Dista Products Company PROD (2002):
  14. "Product Information. Cedax (ceftibuten)." Schering-Plough PROD (2001):
  15. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb PROD (2001):
  16. "Product Information. Omnicef (cefdinir)." Parke-Davis PROD (2001):
  17. "Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals PROD (2001):
  18. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
  19. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
View all 19 references

Ancef drug interactions

There are 39 drug interactions with Ancef (cefazolin).

Ancef alcohol/food interactions

There is 1 alcohol/food interaction with Ancef (cefazolin).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.